Chase Knickerbocker
Stock Analyst at Craig-Hallum
(4.59)
# 229
Out of 4,981 analysts
49
Total ratings
60.42%
Success rate
26.9%
Average return
Main Sectors:
Stocks Rated by Chase Knickerbocker
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INDV Indivior | Maintains: Buy | $27 → $34 | $23.88 | +42.38% | 5 | Aug 27, 2025 | |
| SCPH scPharmaceuticals | Downgrades: Hold | $6 | $5.63 | +6.67% | 3 | Aug 26, 2025 | |
| FENC Fennec Pharmaceuticals | Maintains: Buy | $13 → $14 | $9.03 | +55.04% | 6 | Aug 15, 2025 | |
| PYPD PolyPid | Maintains: Buy | $15 → $13 | $3.45 | +276.81% | 2 | Aug 14, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $6.5 → $11 | $7.68 | +43.23% | 2 | Aug 8, 2025 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | $8 → $11 | $7.28 | +51.10% | 1 | Jul 18, 2025 | |
| BFLY Butterfly Network | Initiates: Buy | $3 | $1.55 | +93.55% | 1 | Jul 1, 2025 | |
| NRXS NeurAxis | Initiates: Buy | $7 | $2.44 | +186.89% | 1 | Jun 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Buy | $12 → $17 | $12.05 | +41.08% | 3 | Jun 9, 2025 | |
| ETON Eton Pharmaceuticals | Maintains: Buy | $26 → $28 | $17.57 | +59.36% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $19.06 | +104.62% | 1 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $1.24 | +545.16% | 4 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $21 | $11.13 | +88.68% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $6 | $4.02 | +49.25% | 2 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $65 | $39.45 | +64.77% | 3 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $12 | $7.14 | +68.07% | 2 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $8.07 | +23.92% | 1 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $23 | $15.86 | +45.02% | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1 → $1.2 | $0.62 | +93.21% | 2 | Jul 11, 2023 |
Indivior
Aug 27, 2025
Maintains: Buy
Price Target: $27 → $34
Current: $23.88
Upside: +42.38%
scPharmaceuticals
Aug 26, 2025
Downgrades: Hold
Price Target: $6
Current: $5.63
Upside: +6.67%
Fennec Pharmaceuticals
Aug 15, 2025
Maintains: Buy
Price Target: $13 → $14
Current: $9.03
Upside: +55.04%
PolyPid
Aug 14, 2025
Maintains: Buy
Price Target: $15 → $13
Current: $3.45
Upside: +276.81%
Xeris Biopharma Holdings
Aug 8, 2025
Maintains: Buy
Price Target: $6.5 → $11
Current: $7.68
Upside: +43.23%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $7.28
Upside: +51.10%
Butterfly Network
Jul 1, 2025
Initiates: Buy
Price Target: $3
Current: $1.55
Upside: +93.55%
NeurAxis
Jun 16, 2025
Initiates: Buy
Price Target: $7
Current: $2.44
Upside: +186.89%
Phathom Pharmaceuticals
Jun 9, 2025
Maintains: Buy
Price Target: $12 → $17
Current: $12.05
Upside: +41.08%
Eton Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $26 → $28
Current: $17.57
Upside: +59.36%
Feb 28, 2025
Initiates: Buy
Price Target: $39
Current: $19.06
Upside: +104.62%
Jan 22, 2025
Maintains: Buy
Price Target: $10 → $8
Current: $1.24
Upside: +545.16%
Jan 17, 2025
Maintains: Buy
Price Target: $18 → $21
Current: $11.13
Upside: +88.68%
Jan 17, 2025
Maintains: Buy
Price Target: $5 → $6
Current: $4.02
Upside: +49.25%
Oct 4, 2024
Maintains: Buy
Price Target: $45 → $65
Current: $39.45
Upside: +64.77%
Aug 1, 2024
Maintains: Buy
Price Target: $14 → $12
Current: $7.14
Upside: +68.07%
Jul 11, 2024
Initiates: Buy
Price Target: $10
Current: $8.07
Upside: +23.92%
May 9, 2024
Maintains: Buy
Price Target: $22 → $23
Current: $15.86
Upside: +45.02%
Jul 11, 2023
Maintains: Buy
Price Target: $1 → $1.2
Current: $0.62
Upside: +93.21%